A Double-Blind, Doubly-Randomized, Placebo-Controlled Study of Intranasal Esketamine in an Adaptive Treatment Protocol to Assess Safety and Efficacy in Treatment-Resistant Depression (SYNAPSE)

Trial Profile

A Double-Blind, Doubly-Randomized, Placebo-Controlled Study of Intranasal Esketamine in an Adaptive Treatment Protocol to Assess Safety and Efficacy in Treatment-Resistant Depression (SYNAPSE)

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2016

At a glance

  • Drugs Esketamine (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms SYNAPSE
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 29 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record..
    • 27 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by Clinicaltrials.gov.
    • 16 Jun 2015 Planned End Date changed from 1 Sep 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top